Skip to main content
    E

    Emergent Biosolutions Inc (EBS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $5.80
    +0.02 (+0.26%)

    Market Cap: $297.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Emergent Biosolutions Inc (EBS) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Emergent Biosolutions (EBS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Emergent Biosolutions reported EPS of -$0.42, above the -$0.45 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -26.07%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.17
    Range-$0.22 - -$0.12
    4 analysts
    Revenue Consensus
    $139.04M
    Range$123.48M - $159.60M
    4 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.53
    Range-$0.53 - -$0.53
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.04-1225.0%
    60d ago-$0.04-1225.0%
    30d ago-$0.04-1225.0%
    7d ago-$0.530.0%
    Current-$0.53
    Revenue Consensus
    $175.00M
    Range$175.00M - $175.00M
    1 analysts

    Next Report

    EBS has an expected report date of Feb 24, 2027.

    EBS Earnings Call

    The latest EBS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, EBS beat 20, missed 19 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $110.00M, down 52.4% from $231.10M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.42-$0.45N/A+6.67%Beat-139.6%21 up, 0 downNov 2, 2026$110.00M
    Jun 30, 2026$0.60$0.11$0.11 - $0.11+445.45%Beat+275.0%10 up, 0 downAug 5, 2026$234.30M
    Mar 31, 2026$0.21-$0.25-$0.25 - -$0.25+184.00%Beat-70.4%10 up, 0 downApr 30, 2026$156.10M
    Dec 31, 2025-$0.43$0.43N/A-201.18%MissN/A10 up, 0 downFeb 26, 2026$148.70M
    Sep 30, 2025$1.06-$0.12-$0.35 - $0.11+983.33%Beat-22.6%21 up, 0 downOct 29, 2025$231.10M
    Jun 30, 2025$0.16-$0.49-$0.72 - -$0.26+132.65%BeatN/A20 up, 1 downAug 6, 2025$140.90M
    Mar 31, 2025$0.71$0.44N/A+61.36%Beat+20.3%10 up, 1 downMay 7, 2025$222.20M
    Dec 31, 2024-$0.58-$0.50-$0.64 - -$0.07-16.50%MissN/A20 up, 0 downMar 3, 2025$194.70M
    Sep 30, 2024$1.37$0.14-$0.21 - $0.49+878.57%BeatN/A20 up, 0 downNov 6, 2024$293.80M
    Jun 30, 2024-$2.32-$0.97-$0.97 - -$0.92-139.18%MissN/A20 up, 0 downAug 6, 2024$254.70M
    Mar 31, 2024$0.59-$0.83-$0.83 - -$0.83+171.08%BeatN/A10 up, 0 downMay 1, 2024$300.40M
    Dec 31, 2023-$0.77-$0.19-$0.33 - $0.07-305.26%MissN/A30 up, 0 downMar 6, 2024N/A
    Sep 30, 2023-$5.08-$0.54-$0.62 - $0.06-840.74%MissN/A30 up, 0 downNov 7, 2023$519.30M
    Jun 30, 2023-$1.06-$0.62-$0.89 - -$0.21-70.97%MissN/A30 up, 1 downAug 8, 2023$978.00M
    Mar 31, 2023-$3.17-$1.34-$1.76 - -$0.80-136.57%Miss-1861.1%51 up, 0 downMay 9, 2023$307.70M
    Dec 31, 2022-$0.31$0.04-$0.16 - $0.45-875.00%Miss-106.9%50 up, 0 downFeb 27, 2023N/A
    Sep 30, 2022-$1.27-$0.13-$0.48 - $0.26-876.92%MissN/A60 up, 0 downNov 8, 2022$239.90M
    Jun 30, 2022-$0.86$0.40-$0.22 - $1.31-315.00%Miss-360.6%60 up, 0 downAug 1, 2022$242.70M
    Mar 31, 2022$0.18$0.13-$0.07 - $0.36+38.46%Beat-88.2%62 up, 0 downApr 28, 2022$307.50M
    Dec 31, 2021$4.50$4.27$3.17 - $4.77+5.39%Beat+22.6%60 up, 1 downFeb 24, 2022$3.50B
    Sep 30, 2021-$0.36$2.28$2.15 - $2.73-115.79%Miss-116.4%60 up, 0 downNov 4, 2021$329.00M
    Jun 30, 2021$0.33$1.56$1.03 - $2.03-78.85%Miss-83.3%6N/AJul 29, 2021$397.50M
    Mar 31, 2021$1.53$1.17$0.85 - $1.57+30.77%Beat+15200.0%7N/AApr 29, 2021$343.00M
    Dec 31, 2020$3.67$3.19$2.59 - $3.86+15.05%Beat+133.8%7N/AFeb 18, 2021$990.10M
    Sep 30, 2020$2.19$2.15$1.93 - $2.46+1.86%Beat+81.0%7N/ANov 5, 2020N/A
    Jun 30, 2020$1.98$0.66$0.53 - $0.79+200.00%Beat+1550.0%6N/AJul 30, 2020$394.70M
    Mar 31, 2020$0.01$0.01-$0.19 - $0.340.00%In lineN/A7N/AApr 30, 2020$192.50M
    Dec 31, 2019$1.57$1.73$1.61 - $1.79-9.25%Miss+109.3%7N/AFeb 20, 2020$360.40M
    Sep 30, 2019$1.21$0.90$0.50 - $1.25+34.44%Beat+120.0%7N/ANov 6, 2019$311.80M
    Jun 30, 2019$0.12$0.18-$0.07 - $0.47-33.33%Miss-88.8%7N/AAug 1, 2019$243.20M
    Mar 31, 2019-$0.13$0.18-$0.03 - $0.23-172.22%MissN/A7N/AMay 2, 2019$190.60M
    Dec 31, 2018$0.75$0.65$0.49 - $0.77+15.38%Beat+1.4%8N/AFeb 21, 2019$270.80M
    Sep 30, 2018$0.55$0.61$0.44 - $0.72-9.84%Miss-24.7%7N/ANov 1, 2018$173.60M
    Jun 30, 2018$1.07$0.93$0.61 - $1.11+15.05%Beat+723.1%7N/AAug 2, 2018$220.20M
    Mar 31, 2018-$0.03$0.17$0.13 - $0.48-117.65%Miss-110.3%6N/AMay 3, 2018$117.80M
    Dec 31, 2017$0.74$0.70$0.63 - $0.74+5.71%Beat0.0%6N/AFeb 22, 2018$193.84M
    Sep 30, 2017$0.73$0.41$0.37 - $0.46+78.05%Beat+25.9%5N/ANov 2, 2017$149.43M
    Jun 30, 2017$0.13$0.26$0.17 - $0.40-50.00%MissN/A5N/AAug 3, 2017$100.77M
    Mar 31, 2017$0.29$0.30N/A-3.33%Miss+81.2%N/AN/AMay 4, 2017$116.86M
    Dec 31, 2016$0.74$0.61N/A+21.31%Beat-5.1%N/AN/AFeb 23, 2017$151.68M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.50, a profit after a loss of $0.94 per share the year before. It was $1.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.50N/A
    Dec 31, 2024-$0.94N/A
    Dec 31, 2023-$10.08N/A
    Dec 31, 2022-$2.26-137.7%
    Dec 31, 2021$6.00-23.6%
    Dec 31, 2020$7.85+183.4%
    Dec 31, 2019$2.77+18.4%
    Dec 31, 2018$2.34+23.8%
    Dec 31, 2017$1.89+45.4%
    Dec 31, 2016$1.30N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,4736
    2026Q2Jun 30, 20265,3117
    2026Q1Mar 31, 20264,3328
    2025Q4Dec 31, 20252,8894
    2025Q3Sep 30, 20254,3466
    2025Q2Jun 30, 20255,3425
    2025Q1Mar 31, 20252,0646
    2024Q4Dec 31, 20245,3996

    2026Q3 Earnings Call

    Opening remarks

    Frank Vargo VP and Treasurer Good afternoon, everyone, and thank you for joining us as Emergent discusses its operational and financial results for the third quarter of 2026. As is customary, today's call is open to all participants, is being recorded and is copyrighted by Emergent BioSolutions. In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants. Turning to Slide 2. During today's call, Emergent may make projections and other forward-looking statements related to business, future events, prospects or future performance. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. Any forward-looking statements speak only as of the date of this conference call, and except as required by law, Emergent does not undertake to update any forward-looking statements to reflect new information, events or circumstances. Investors should consider this cautionary statement as well as the risk factors identified in Emergent's periodic reports filed with the SEC when evaluating these forward-looking statements. During today's call, Emergent may also discuss certain non-GAAP financial measures that include adjustments to GAAP figures to provide additional transparency regarding the company's operating performance. Please refer to the tables included in today's press release. Turning to Slide 3. The agenda for today's call includes remarks from Joe Papa, President and Chief Executive Officer, who will provide an update on the company's transformation plan, business performance and key highlights. Rich Lindahl, EVP and Chief Financial Officer, will then review the third quarter 2026 financial results and provide an update on full-year 2026 guidance. Joe Papa will conclude with a discussion of the company's key catalysts for growth, followed by a question-and-answer session. Finally, for the benefit of those who may be listening to the replay of this webcast, this call is held and recorded on November 2, 2026. Since that time, Emergent may have made announcements related to topics discussed during today's call. With that, I will now turn the call over to Joe Papa. Joe?

    Joseph Papa President and Chief Executive Officer Hello, everyone, and thank you for joining us to discuss Emergent's third quarter 2026 financial results. This is Joe Papa, President and Chief Executive Officer of Emergent. And I'm joined today by Rich Lindahl, our Chief Financial Officer. This afternoon, I will share an update on our multiyear transformation plan, the actions we implemented during the quarter to strengthen the business and the progress we are making across our diversified medical countermeasure and naloxone portfolios. Rich will then review our third quarter financial results and our outlook for the remainder of 2026. I will close with the growth catalysts and priorities that will guide us as we finish the year. Then we'll open up the call for Q&A.

    Frequently Asked Questions About EBS

    When is Emergent Biosolutions's next earnings date?

    Emergent Biosolutions's next earnings report is expected for Feb 24, 2027.

    Did EBS beat earnings estimates last quarter?

    Yes. Emergent Biosolutions reported EPS of -$0.42 for the quarter ended Sep 30, 2026, above the -$0.45 estimate, a 6.67% surprise.

    What EPS do analysts expect from EBS next quarter?

    The consensus EPS estimate for Emergent Biosolutions for the quarter ending Dec 31, 2026 is -$0.17 from 4 analysts, with estimates from -$0.22 to -$0.12.

    How often does EBS beat earnings estimates?

    Emergent Biosolutions beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +199.47%.